Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?
At present, empirical radioactive iodine therapy is recommended for patients with thyroid cancer and elevated thyroglobulin (Tg) after initial therapy when neck ultrasonography (US), chest computed tomography (CT), and 18-fluorodeoxyglucose positron emission tomography (FDG-PET) do not reveal metastases. The objective of this study was to determine whether empirical (131)I therapy is indeed useful in these patients. Patients with papillary thyroid cancer submitted to total thyroidectomy followed by remnant ablation with (131)I in whom whole-body scanning at the time of ablation (WBS-ablation) did not reveal metastases and who had elevated Tg after initial therapy were selected. Included in the study were patients with basal Tg >2 ng/mL or Tg >5 ng/mL after stimulation with recombinant human thyrotropin or Tg >10 ng/mL after levothyroxine withdrawal for 4 weeks. All patients were first investigated by neck US and chest CT. FDG-PET/CT was performed in patients with negative US and CT. The final sample of this study consisted of patients with negative US, CT, and FDG-PET/CT. These patients received an activity of 100 mCi (131)I and were submitted to posttherapy WBS (RxWBS). Among the 24 patients receiving empirical (131)I therapy, no ectopic uptake was seen in 23 and mild uptake in the thyroid bed (<0.5%) in 15. Only one patient presented pulmonary metastases detected by RxWBS. Disease was observed in two other patients during short-term follow-up (mean 22 months), one with lymph node metastases diagnosed by a repeat US and one with bone metastases diagnosed by CT and FDG-PET scans. We conclude that RxWBS rarely reveals disease in patients with elevated Tg after ablation, but with negative findings on WBS-ablation, US, CT, and FDG-PET. In this situation, empirical (131)I therapy should be restricted to patients with documented progression of serum Tg.